Citations

Showing 10 of 108083 citations.

The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium
Demarest, Scott , Shellhaas, Renée A. , Gaillard, William D. , Keator, Cynthia, Nickels, Katherine , Loddenkemper, Tobias , Saneto, Russell P. , Fernández, Iván Sánchez , Chu, Catherine J. , Wusthoff, Courtney J. , Joshi, Sucheta M. , Mohamed, Ismail , Stafstrom, Carl E. , Stack, Cynthia V. , Yozawitz, Elissa , Bluvstein, Judith , Singh, Rani K. , Demarest, Scott T , Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Chu, Catherine J , Nickels, Katherine C , Hussain, Shaun A. , Patel, Anup D. , Wirrell, Elaine , Grinspan, Zachary M. , Knupp, Kelly G. , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | November 3, 2017 | Volume: 58 | Issue: 12 | Pages: 2098-2103

10.1111/epi.13937 | PMID 29105055 Get It

SummaryObjectiveThe multicenter National Infantile Spasms Consortium prospective cohort was used to compare outcomes and phenotypic features of patients with infantile spasms with and without hypsarrhythmia.MethodsPatients aged 2 months to 2 years were enrolled prospectively with new‐onset infantile spasms. Treatment choice and categorization of hypsarrhythmia were determined clinically at each site. Response to therapy was defined as resolution of clinical spasms (and hypsarrhythmia if present) without relapse 3 months after initiation.ResultsEighty‐two percent of patients had hypsarrhythmia, but this was not associated with gender, mean age, preexisting developmental delay or epilepsy, etiology, or response to first‐line therapy. Infants with hypsarrhythmia were more likely to receive standard treatment (adrenocorticotropic hormone, prednisolone, or vigabatrin [odds ratio (OR) 2.6, 95% confidence interval (CI) 1.4–4.7] and preexisting epilepsy reduced the likelihood of standard treatment (OR3.2, 95%CI1.9–5.4). Hypsarrhythmia was not a determinant of response to treatment. A logistic regression model demonstrated that later age of onset (OR1.09 per month, 95%CI1.03–1.15) and absence of preexisting epilepsy (OR1.7, 95%CI1.06–2.81) had a small impact on the likelihood of responding to the first‐line treatment. However, receiving standard first‐line treatment increased the likelihood of responding dramatically: vigabatrin (OR5.2 ,95%CI2–13.7), prednisolone (OR8, 95%CI3.1–20.6), and adrenocorticotropic hormone (ACTH;OR10.2, 95%CI4.1–25.8) .SignificanceFirst‐line treatment with standard therapy was by far the most important variable in determining likelihood of response to treatment of infantile spasms with or without hypsarrhythmia.
Left Lateral Thoracotomy for Centrifugal Continuous-Flow Left Ventricular Assist Device Placement: An Analysis from the Mechanical Circulatory Support Research Network
Maltais, Simon, Anwer, Lucman A. , Tchantchaleishvili, Vakhtang , Haglund, Nicholas, Cowger, Jennifer , Salerno, Christopher T. , Shah, Palak , Khalpey, Zain , Schmitto, Jan D. , Stulak, John M., Dunlay, Shannon M. , Tchantchaleishvili, Vakhtang , Aaronson, Keith D. , Pagani, Francis D. , Shah, Palak

Mayo Clinic

ASAIO Journal | November 3, 2017 | Volume: 64 | Issue: 6 | Pages: 715-720

10.1097/mat.0000000000000714 | PMID 29095733 Get It

Continuous-flow left ventricular assist devices (CF-LVADs) have revolutionized the management of patients with advanced heart failure. Alternative implant strategies are increasingly used for device placement. We reviewed our experience from the Mechanical Circulatory Support Research Network registry with the HeartWare centrifugal CF-LVAD (HVAD). From May 2004 to August 2015, 1,150 patients underwent primary CF-LVAD implantation at our institutions. Within this group, a total of 283 patients (25%) were implanted with the HVAD. A minimally invasive left lateral thoracotomy (MILT) implant strategy was used in 53 patients (20%), of which 22 (42%) were implanted off-pump. Median age at implant was 59 years and 183 patients (65%) were implanted as bridge-to-transplantation. Follow-up was 100% complete for a total of 302 patient-years of support. In-hospital mortality was 4.9% (14 patients), and was comparable between the conventional sternotomy (CS) and MILT cohorts (p = 0.15). Patients in the MILT cohort had a shorter median length of stay (p < 0.01) and had a lower incidence of postimplant pump thrombus (p = 0.02). Cumulative survival at the end of follow-up reached 84%, and was comparable between the two groups (p = 0.298). Multivariate analysis identified preoperative bilirubin level as the only independent predictor of survival. Surgical technique had no impact on survival. In this large, multicenter experience, data demonstrate excellent survival and adverse event profiles for patients supported with the HVAD technology, regardless of surgical implant technique. With constant advancements in device technology along with our increasing clinical experience with the newer techniques, minimally invasive LVAD implantation continues to evolve as a valuable alternative to CS in selected patients.
Single Versus Multidrug Regimen for Surgical Infection Prophylaxis in Left Ventricular Assist Device Implantation
Aburjania, Nana , Ertmer, Brennan, Farid, Saira, Berg, Melody L. , Nienaber, Juhsien J. C., Tchantchaleishvili, Vakhtang , Stulak, John M., Sohail, M. Rizwan , Ertmer, Brennan M, Sohail, Muhammad R, Sohail, M Rizwan , Tchantchaleishvili, Vakhtang , Baddour, Larry M.

Mayo Clinic

ASAIO Journal | November 3, 2017 | Volume: 64 | Issue: 6 | Pages: 735-740

10.1097/mat.0000000000000710 | PMID 29095735 Get It

Infection is a serious complication of left ventricular assist device (LVAD) therapy. However, an optimal antimicrobial surgical infection prophylaxis (SIP) regimen for LVAD implantation is not well established. We retrospectively reviewed all adults who underwent continuous-flow LVAD implantation from February 2007 to March 2015 at Mayo Clinic Rochester. Left ventricular assist device infection (LVADI) was defined using criteria published by the International Society for Heart and Lung Transplant. Patients excluded from the analysis included those who did not have HeartMate II or HeartWare device, patients with incomplete documentation of SIP, and those with an actively treated infection at the time of LVAD implantation. We compared risk of LVAD-specific and LVAD-related infections and all-cause mortality between SIP regimens at postoperative day 90 and 1 year using Kaplan–Meier time-to-event analyses. During study period, 239 adults underwent continuous-flow LVAD implantation at our institution where 199 patients received single-drug and 40 received multidrug SIP regimen. Median patient age was 62 years. Left ventricular assist device infection occurred in three patients (1.5%) in the single-drug group versus two patients (5.0%) in the multidrug group at 90 days (p = 0.4). There was no difference in infection-free (p = 0.4) and overall survival (p = 0.9) between two groups at 1 year. In conclusion, there was no clear benefit of using multidrug regimen as it did not impact infection-free survival or all-cause mortality compared with single-drug regimen. Prospective clinical trials are needed to further define the optimal SIP regimen for LVAD implantation.
Left Ventricular Assist Device Infections: A Systematic Review
O’Horo, John C. , Saleh, Omar Abu , Stulak, John M., Wilhelm, Mark , Sohail, M. Rizwan , Abu Saleh, Omar M, Wilhelm, Mark P, Sohail, M Rizwan , O'Horo, John C , Baddour, Larry M.

Mayo Clinic

ASAIO Journal | November 3, 2017 | Volume: 64 | Issue: 3 | Pages: 287-294

10.1097/mat.0000000000000684 | PMID 29095732 Get It

Left ventricular assist devices (LVADs) are becoming a more frequent life-support intervention. Gaining an understanding of risk factors for infection and management strategies is important for treating these patients. We conducted a systematic review and meta-analysis of studies describing infections in continuous-flow LVADs. We evaluated incidence, risk factors, associated microorganisms, and outcomes by type of device and patient characteristics. Our search identified 90 distinct studies that reported LVAD infections and outcomes. Younger age and higher body mass index were associated with higher rates of LVAD infections. Driveline infections were the most common infection reported and the easiest to treat with fewest long-term consequences. Bloodstream infections were not reported as often, but they were associated with stroke and mortality. Treatment strategies varied and did not show a consistent best approach. LVAD infections are a significant cause of morbidity and mortality in LVAD patients. Most research comes from secondary analyses of other LVAD studies. The lack of infection-oriented research leaves several areas understudied. In particular, bloodstream infections in this population merit further research. Providers need more research studies to make evidence-based decisions about the prevention and treatment of LVAD infections.
Can Lung Ultrasound Be the First-Line Tool for Evaluation of Intraoperative Hypoxemia?
Díaz‐Gómez, José L. , Ratzlaff, Robert A. , Via, Gabriele , Torp, Klaus D. , Ramakrishna, Harish , Díaz-Gómez, José L , Renew, J. Ross

Mayo Clinic

Anesthesia & Analgesia | November 3, 2017 | Volume: 126 | Issue: 5 | Pages: 1769-1773

10.1213/ane.0000000000002578 | PMID 29099431 Get It

The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants
Leffert, Lisa , Butwick, Alexander J. , Bates, Shannon M. , Friedman, Alex, Horlocker, Terese T. , Houle, Timothy T. , Arendt, Katherine, Horlocker, Terese, Carvalho, Brendan , Arendt, Katherine W. , Landau, Ruth

Mayo Clinic

Anesthesia & Analgesia | November 3, 2017 | Volume: 126 | Issue: 3 | Pages: 928-944

10.1213/ane.0000000000002530 | PMID 29099429 Get It

Venous thromboembolism is recognized as a leading cause of maternal death in the United States. Thromboprophylaxis has been highlighted as a key preventive measure to reduce venous thromboembolism–related maternal deaths. However, the expanded use of thromboprophylaxis in obstetrics will have a major impact on the use and timing of neuraxial analgesia and anesthesia for women undergoing vaginal or cesarean delivery and other obstetric surgeries. Experts from the Society of Obstetric Anesthesia and Perinatology, the American Society of Regional Anesthesia, and hematology have collaborated to develop this comprehensive, pregnancy-specific consensus statement on neuraxial procedures in obstetric patients receiving thromboprophylaxis or higher dose anticoagulants. To date, none of the existing anesthesia societies’ recommendations have weighed the potential risks of neuraxial procedures in the presence of thromboprophylaxis, with the competing risks of general anesthesia with a potentially difficult airway, or maternal or fetal harm from avoidance or delayed neuraxial anesthesia. Furthermore, existing guidelines have not integrated the pharmacokinetics and pharmacodynamics of anticoagulants in the obstetric population. The goal of this consensus statement is to provide a practical guide of how to appropriately identify, prepare, and manage pregnant women receiving thromboprophylaxis or higher dose anticoagulants during the ante-, intra-, and postpartum periods. The tactics to facilitate multidisciplinary communication, evidence-based pharmacokinetic and spinal epidural hematoma data, and Decision Aids should help inform risk–benefit discussions with patients and facilitate shared decision making.
Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma
Giridhar, Karthik V. , Sosa, Carlos, Sanhueza, Cristobal T., Dalpiaz, Candace Lee, Costello, Brian A. , Pitot, Henry C., Dronca, Roxana , Ertz, Donna, Cheville, John C. , Donkena, Krishna Vanaja, Sosa, Carlos P., Hillman, David W. , Sanhueza, Cristobal, Dalpiaz, Candace L, Quevedo, Fernando J, Dronca, Roxana S., Kohli, Manish , Giridhar, Karthik V , Quevedo, Fernando

Mayo Clinic

International Journal of Molecular Sciences | November 3, 2017 | Volume: 18 | Issue: 11 | Pages: 2326

10.3390/ijms18112326 | PMID 29099775 Get It

The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. We analyzed whole blood mRNA expression in metastatic clear cell renal cell carcinoma (mCCRCC) patients and compared it to the MSKCC score for predicting overall survival. In a discovery set of 19 patients with mRCC, we performed whole transcriptome RNA sequencing and selected eighteen candidate genes for further evaluation based on associations with overall survival and statistical significance. In an independent validation of set of 47 patients with mCCRCC, transcript expression of the 18 candidate genes were quantified using a customized NanoString probeset. Cox regression multivariate analysis confirmed that two of the candidate genes were significantly associated with overall survival. Higher expression of BAG1 [hazard ratio (HR) of 0.14, p < 0.0001, 95% confidence interval (CI) 0.04–0.36] and NOP56 (HR 0.13, p < 0.0001, 95% CI 0.05–0.34) were associated with better prognosis. A prognostic model incorporating expression of BAG1 and NOP56 into the MSKCC score improved prognostication significantly over a model using the MSKCC prognostic score only (p < 0.0001). Prognostic value of using whole blood mRNA gene profiling in mCCRCC is feasible and should be prospectively confirmed in larger studies.
How guiding coalitions promote positive culture change in hospitals: a longitudinal mixed methods interventional study
Bradley, Elizabeth H. , Brewster, Amanda L. , McNatt, Zahirah , Linnander, Erika , Cherlin, Emily , Fosburgh, Heather, Ting, Henry H. , Curry, Leslie , Fosburgh, Heather

Mayo Clinic

BMJ Quality & Safety | November 3, 2017 | Volume: 27 | Issue: 3 | Pages: 218-225

10.1136/bmjqs-2017-006574 | PMID 29101290 Get It

Background Quality collaboratives are widely endorsed as a potentially effective method for translating and spreading best practices for acute myocardial infarction (AMI) care. Nevertheless, hospital success in improving performance through participation in collaboratives varies markedly. We sought to understand what distinguished hospitals that succeeded in shifting culture and reducing 30-day risk-standardised mortality rate (RSMR) after AMI through their participation in the Leadership Saves Lives (LSL) collaborative. Procedures We conducted a longitudinal, mixed methods intervention study of 10 hospitals over a 2-year period; data included surveys of 223 individuals (response rates 83%–94% depending on wave) and 393 in-depth interviews with clinical and management staff most engaged with the LSL intervention in the 10 hospitals. We measured change in culture and RSMR, and key aspects of working related to team membership, turnover, level of participation and approaches to conflict management. Main findings The six hospitals that experienced substantial culture change and greater reductions in RSMR demonstrated distinctions in: (1) effective inclusion of staff from different disciplines and levels in the organisational hierarchy in the team guiding improvement efforts (referred to as the ‘guiding coalition’ in each hospital); (2) authentic participation in the work of the guiding coalition; and (3) distinct patterns of managing conflict. Guiding coalition size and turnover were not associated with success (p values>0.05). In the six hospitals that experienced substantial positive culture change, staff indicated that the LSL learnings were already being applied to other improvement efforts. Principal conclusions Hospitals that were most successful in a national quality collaborative to shift hospital culture and reduce RSMR showed distinct patterns in membership diversity, authentic participation and capacity for conflict management.
Influencing organisational culture to improve hospital performance in care of patients with acute myocardial infarction: a mixed-methods intervention study
Curry, Leslie , Brault, Marie A. , Linnander, Erika , McNatt, Zahirah , Brewster, Amanda L. , Cherlin, Emily , Flieger, Signe Peterson , Ting, Henry H. , Bradley, Elizabeth H.

Mayo Clinic

BMJ Quality & Safety | November 3, 2017 | Volume: 27 | Issue: 3 | Pages: 207-217

10.1136/bmjqs-2017-006989 | PMID 29101292 Get It

Background Hospital organisational culture affects patient outcomes including mortality rates for patients with acute myocardial infarction; however, little is known about whether and how culture can be positively influenced. Methods This is a 2-year, mixed-methods interventional study in 10 US hospitals to foster improvements in five domains of organisational culture: (1) learning environment, (2) senior management support, (3) psychological safety, (4) commitment to the organisation and (5) time for improvement. Outcomes were change in culture, uptake of five strategies associated with lower risk-standardised mortality rates (RSMR) and RSMR. Measures included a validated survey at baseline and at 12 and 24 months (n=223; average response rate 88%); in-depth interviews (n=393 interviews with 197 staff); and RSMR data from the Centers for Medicare and Medicaid Services. Results We observed significant changes (p<0.05) in culture between baseline and 24 months in the full sample, particularly in learning environment (p<0.001) and senior management support (p<0.001). Qualitative data indicated substantial shifts in these domains as well as psychological safety. Six of the 10 hospitals achieved substantial improvements in culture, and four made less progress. The use of evidence-based strategies also increased significantly (per hospital average of 2.4 strategies at baseline to 3.9 strategies at 24 months; p<0.05). The six hospitals that demonstrated substantial shifts in culture also experienced significantly greater reductions in RSMR than the four hospitals that did not shift culture (reduced RSMR by 1.07 percentage points vs 0.23 percentage points; p=0.03) between 2011–2014 and 2012–2015. Conclusions Investing in strategies to foster an organisational culture that supports high performance may help hospitals in their efforts to improve clinical outcomes.